Pilot corpus: NIH-funded biomedical datasets. Any DOI can be scored on demand — network effects sharpen as coverage grows.

Can We Predict Who Will Experience Adverse Events While Using Smoking Cessation Pharmacotherapy? A Secondary Analysis of the EAGLES Clinical Trial

Nicotine & Tobacco Research(2024)10.1093/ntr/ntae290Source: DataRank Database

Can We Predict Who Will Experience Adverse Events While Using Smoking Cessation Pharmacotherapy? A Secondary Analysis of the EAGLES Clinical Trial is a research paper published in Nicotine & Tobacco Research (2024). On theSindex it has a DataRank of 0. It has been cited 1 time.

N/A

0DataRank · unranked

Scored on demand from live citation data

Open Access1 citations

Download PDF

Cite:

Linked data & code

Predicting Individuals' Probability of Response to Smoking Cessation Pharmacotherapy · Vivli

DataRank reads this dataset's downstream impact straight off the citation graph — no black box, no proprietary weighting. How is this computed?

›Methodology & internals

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Pipeline:MetadataData-paper checkEnrichmentCitation networkScoring

Enrichment:Funding (1 grants)Impact (FWCI 0.24)OA: greenTopics (26)Linked Datasets (1)DataCite Reuse (1)IDs (PubMed, PMC, OpenAlex)SDGs (1)

FAIR Checklist

Context only (not used in score)

Findable (2/2)

Has DOI
Indexed in repositories

Accessible (1/2)

Open Access

Interoperable (2/2)

DataCite relations
Linked datasets

Reusable (0/3)

FAIR checklist signals are shown for context only and do not affect DataRank scoring.

Run a calibrated FAIR evaluation for this paper →

We only score data papers we can read in full — never from an abstract alone.

Authors (5)

Kevin M. Gray ORCID,Jennifer Dahne ORCID,Daniel Hashemi ORCID,Rachel L. Tomko ORCID,Bethany J. Wolf ORCID

Live enrichment

PubMed:39658081 PMC:PMC12012235 OpenAlex:https://openalex.org/W4405219200

National Cancer Institute

Grant: R03CA270677

FWCI

0.24

Citation Percentile

0.6%

Citation Trend

2026

greenLicense: https://academic.oup.com/pages/standard-publication-reuse-rights

repositoryhttps://pmc.ncbi.nlm.nih.gov/articles/PMC12012235/pdf/ntae290.pdf

publisherhttps://academic.oup.com/ntr/advance-article-pdf/doi/10.1093/ntr/ntae290/61200074/ntae290.pdf

publisherhttps://academic.oup.com/ntr/article-pdf/27/5/839/61200074/ntae290.pdf

repositoryhttps://pmc.ncbi.nlm.nih.gov/articles/PMC12012235/

Fields of Study

Smoking Behavior and CessationAdvanced Causal Inference TechniquesSubstance Abuse Treatment and Outcomes

MeSH Terms

VareniclineSmoking Cessation AgentsAdultFemaleHumansMaleMiddle AgedUnited StatesSmoking CessationBupropionTobacco Use Cessation Devices

Keywords

VareniclinePharmacotherapyBupropionSmoking cessationNicotine replacement therapyMedicineOddsAdverse effectPsychiatryPharmacologyInternal medicineLogistic regression

Sustainable Development Goals

SDG 0: Good health and well-being

Predicting Individuals' Probability of Response to Smoking Cessation Pharmacotherapy

10.25934/pr00004915Vivli